Overcoming Treatment Barriers: How DHTs Can Facilitate Widespread Outpatient Immunotherapy Treatments

Emerging immunotherapies, including CAR-T cell and T-cell engager therapies, have transformed cancer treatment. Despite their promise, these therapies carry significant risks. This edition of Digital Health Monthly, explores how the risk of cytokine release syndrome (CRS) impacts immunotherapy adoption and the urgent need for innovative solutions to support safer, broader use. Drawing from the perspectives of patients, clinicians, and developers, our expert panel addresses the clinical and logistical challenges posed by CRS and how digital health technologies (DHTs) can help mitigate them.

The session highlights how DHTs enable remote, real-time monitoring to detect early signs of CRS, enhancing both patient safety and trial efficiency. Panelists present feasibility data from immunotherapy trials that have integrated remote monitoring tools, and they share valuable insights on implementation challenges and opportunities. Attendees will gain a clear understanding of how the industry is leveraging digital innovation to manage immunotherapy risks and the critical next steps toward deploying scalable, technology-driven CRS monitoring solutions.